Riluzole Prodrugs for Melanoma and ALS

治疗黑色素瘤和 ALS 的利鲁唑前药

基本信息

项目摘要

DESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action, and also be useful to treat amyotrophic lateral sclerosis (ALS) and the many other conditions for which riluzole itself is under clinical evaluation. FC-311 is not subject to the limiting Cyp1A2 metabolism and large patient-to-patient variability of exposure that riluzole is, and has a ~3X longer high-life, higher bioavailability upon oral administration, and shows dramatic efficacy in a xenograft model of melanoma, in a dose dependent manner. We identified FC-311 as the optimal prodrug from among ~30 designed candidates using a systematic in vitro and in vivo screening strategy. We have demonstrated conclusively that FC-311 is not metabolized by Cyp1A2, while confirming that riluzole itself is metabolized nearly exclusively by this enzyme, which has variable levels of expression in the general population. We have achieved all of the aims of our Phase I program of study as well as conducted many additional studies that were not originally described or anticipated. We now seek Phase II support to advance FC-311 through various IND-enabling pre-clinical development activities. Our goal is to develop FC-311 as an oral anticancer agent in order to provide uniform, patient to patient delivery of riluzole active substance. In Aim 1, we will conduct drug substance and chemistry related activities normally considered as part of any drug discovery and development program. These include preparing 300 g of non-GMP active pharmaceutical agent, selection of suitable salt form, vehicle and formulation, analytical methods development, drug substance stability testing, evaluation of additional riluzole prodrugs for added patent protection, as back-ups, and for possible consideration for additional indications, continued patent prosecution of the important intellectual property involved, and preparation of 5 kg of cGMP of FCC-311. In Aim 2, we will continue the required IND-enabling development activities which include completion of metabolite ID studies (human, rat and dog), determination of full PK parameters in two additional species, correlated to pharmacodynamics, investigation of Cyp450 inhibition effect in addition to the demonstrated lack of Cyp1A2, completion of in vitro, non-GLP toxicology studies (hERG, Ames, genotoxicity), 28 day safety pharmacology testing in rats and dogs, and further ancillary pharmacology testing on FC-311. We wish to file an IND with the FDA as soon as possible, and then transition into clinical evaluation in melanoma patients. We have established a Riluzole Prodrug Project Leadership Team consisting of eight clinicians, pharmacologists and experienced pharmaceutical experts to provide real time guidance and support to ensure the success of this program. We will file for orphan drug designation for FC-311 for melanoma, and seek to obtain further funding from venture capital and other sources, or partner with a major pharmaceutical company, to advance FC-311 through the various phases of clinical development.
描述(由申请人提供):我们已经鉴定了利鲁唑的新型IIb型前药FC-311,其具有通过新型神经递质作用机制起作用的革命性治疗转移性黑色素瘤的破坏性病症的疗法的潜力,并且还可用于治疗肌萎缩性侧索硬化症(ALS)和利鲁唑本身处于临床评价中的许多其他病症。FC-311不受利鲁唑的Cyp 1A 2代谢限制和较大的患者间暴露变异性的影响,口服给药后,FC-311的高寿命期约为利鲁唑的3倍,生物利用度更高,并以剂量依赖性方式在黑素瘤异种移植模型中显示出显著疗效。我们使用系统的体外和体内筛选策略,从约30种设计的候选药物中确定FC-311为最佳前药。我们已经最终证明FC-311不被Cyp 1A 2代谢,同时证实利鲁唑本身几乎完全被这种酶代谢,这种酶在一般人群中的表达水平不同。我们已经实现了I期研究计划的所有目标,并进行了许多最初没有描述或预期的额外研究。我们现在寻求II期支持,以通过各种IND使能临床前开发活动来推进FC-311。我们的目标是将FC-311开发为口服抗癌药,以提供利鲁唑活性物质的患者间均匀给药。在目标1中,我们将开展通常被视为任何药物发现和开发计划一部分的原料药和化学相关活动。这些包括制备300 g非GMP活性药剂,选择合适的盐形式、载体和制剂,分析方法开发,原料药稳定性测试,评估额外的利鲁唑前药以增加专利保护,作为备份,并可能考虑额外的适应症,继续对所涉及的重要知识产权进行专利起诉,和制备5 kg FCC-311的cGMP。在目标2中,我们将继续开展所需的IND开发活动,包括完成代谢物ID研究(人、大鼠和犬),在另外两个种属中测定与药效学相关的完整PK参数,除了证明缺乏Cyp 1A 2外,还研究Cyp 450抑制作用,完成体外非GLP毒理学研究(hERG、艾姆斯、遗传毒性)、大鼠和犬28天安全性药理学试验以及FC-311的进一步辅助药理学试验。我们希望尽快向FDA提交IND,然后过渡到黑色素瘤患者的临床评价。我们已经成立了一个由八名临床医生、药理学家和经验丰富的药学专家组成的阿舒唑前药项目领导小组,以提供真实的时间指导和支持,确保该项目的成功。我们将为FC-311申请孤儿药资格,并寻求从风险投资和其他来源获得更多资金,或与大型制药公司合作,以推进FC-311通过临床开发的各个阶段。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Allen Bernard Reitz其他文献

Allen Bernard Reitz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Allen Bernard Reitz', 18)}}的其他基金

Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders
针对 TDP-43 治疗阿尔茨海默病及相关疾病的疗法
  • 批准号:
    10436955
  • 财政年份:
    2021
  • 资助金额:
    $ 95.96万
  • 项目类别:
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders
针对 TDP-43 治疗阿尔茨海默病及相关疾病的疗法
  • 批准号:
    10662334
  • 财政年份:
    2021
  • 资助金额:
    $ 95.96万
  • 项目类别:
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders
针对 TDP-43 治疗阿尔茨海默病及相关疾病的疗法
  • 批准号:
    10210993
  • 财政年份:
    2021
  • 资助金额:
    $ 95.96万
  • 项目类别:
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders
针对 TDP-43 治疗阿尔茨海默病及相关疾病的疗法
  • 批准号:
    10621622
  • 财政年份:
    2021
  • 资助金额:
    $ 95.96万
  • 项目类别:
PET Imaging Agents for the in vivo Detection of TDP-43
用于 TDP-43 体内检测的 PET 成像剂
  • 批准号:
    9409556
  • 财政年份:
    2017
  • 资助金额:
    $ 95.96万
  • 项目类别:
DEVELOPMENT OF DRUGS THAT TARGET THE M2 PROTON CHANNEL FROM INFLUENZA A VIRUS
开发针对甲型流感病毒 M2 质子通道的药物
  • 批准号:
    9247305
  • 财政年份:
    2016
  • 资助金额:
    $ 95.96万
  • 项目类别:
New therapeutics for the treatment of Acinetobactor baumannii infections.
治疗鲍曼不动杆菌感染的新疗法。
  • 批准号:
    8597861
  • 财政年份:
    2013
  • 资助金额:
    $ 95.96万
  • 项目类别:
DC-SIGN Inhibitors for the Treatment of HIV Infection
用于治疗 HIV 感染的 DC-SIGN 抑制剂
  • 批准号:
    8542379
  • 财政年份:
    2013
  • 资助金额:
    $ 95.96万
  • 项目类别:
Riluzole Prodrugs for Melanoma and ALS
治疗黑色素瘤和 ALS 的利鲁唑前药
  • 批准号:
    8057154
  • 财政年份:
    2011
  • 资助金额:
    $ 95.96万
  • 项目类别:
Riluzole Prodrugs for Melanoma and ALS
治疗黑色素瘤和 ALS 的利鲁唑前药
  • 批准号:
    8524856
  • 财政年份:
    2011
  • 资助金额:
    $ 95.96万
  • 项目类别:

相似海外基金

Molecular Simulations of Additive Self-Assembly, Rheology, and Surface Adsorption in Complex Fluids
复杂流体中添加剂自组装、流变学和表面吸附的分子模拟
  • 批准号:
    2901619
  • 财政年份:
    2024
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Studentship
An Adsorption-Compression Cold Thermal Energy Storage System (ACCESS)
吸附压缩冷热能存储系统(ACCESS)
  • 批准号:
    EP/W027593/2
  • 财政年份:
    2024
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Research Grant
Tuning Precision Fabricated Liquid Crystal Adsorbents - Toward Tailored Adsorption of Per- and Polyfluorinated Alkyl Substances
调整精密制造的液晶吸附剂 - 针对全氟和多氟烷基物质的定制吸附
  • 批准号:
    24K17729
  • 财政年份:
    2024
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Thermal stability of adsorption solar power plants
吸附式太阳能发电厂的热稳定性
  • 批准号:
    2871817
  • 财政年份:
    2024
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Studentship
Computational Studies of Gas Adsorption in Special Nuclear Materials (SNMs).
特殊核材料(SNM)中气体吸附的计算研究。
  • 批准号:
    2903366
  • 财政年份:
    2024
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Studentship
Collaborative Research: Integrated experiments and simulations to understand the mechanism and consequences of polymer adsorption in films and nanocomposites
合作研究:综合实验和模拟来了解薄膜和纳米复合材料中聚合物吸附的机制和后果
  • 批准号:
    2312325
  • 财政年份:
    2023
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Standard Grant
Metal tolerance and metal adsorption through phycosphere control
通过藻圈控制实现金属耐受性和金属吸附
  • 批准号:
    23H02303
  • 财政年份:
    2023
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Investigation of adsorption of exosomes on porous materials and regulating the behavior to create separation, purification and preservation techniques
研究外泌体在多孔材料上的吸附并调节行为以创建分离、纯化和保存技术
  • 批准号:
    23KJ0192
  • 财政年份:
    2023
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Reflection and adsorption of low energy hydrogen on solid surface
低能氢在固体表面的反射与吸附
  • 批准号:
    23H01158
  • 财政年份:
    2023
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Super-Resolution Imaging of Surface Adsorption on Single Nanoparticles for Electrochemical Dechlorination
用于电化学脱氯的单个纳米颗粒表面吸附的超分辨率成像
  • 批准号:
    2303933
  • 财政年份:
    2023
  • 资助金额:
    $ 95.96万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了